Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company is stepping back in second-line breast cancer.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.